Retatrutide is being studied in people with obesity, overweight and type 2 diabetes, but it is not currently approved as a diabetes or weight loss treatment in the UK
If regulatory approval, prescription access, and insurance coverage matter, tirzepatide is the only option
The good news is that many users of branded GLP-1s qualify for partial or full insurance coverage, especially if they have diabetes or a BMI over 30
The GIP component may further support metabolic function, though the precise contribution of GIP receptor agonism to weight loss and insulin sensitivity in humans remains an area of active research
This fibrous tissue is denser and less compliant than healthy subcutaneous fat, making subsequent injections in that area more uncomfortable
Endocrinol 128:31753182 Rocca AS, Brubaker PL (1999) Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion